<DOC>
	<DOCNO>NCT01611272</DOCNO>
	<brief_summary>To identify follow item post marketing surveillance routine clinical practice marketing authorization Brilinta Tablet : occurrence unrevealed Serious Adverse Events ( SAEs ) , current status occurrence Adverse Events ( AEs ) , factor may influence safety efficacy drug .</brief_summary>
	<brief_title>A Post Marketing Surveillance Evaluate Safety Efficacy Brilinta</brief_title>
	<detailed_description>A Post Marketing Surveillance evaluate safety efficacy Brilinta</detailed_description>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Ticagrelor</mesh_term>
	<criteria>Patients Acute Coronary Syndromes Patients take ticagrelor ASA daily ( 75150mg ) , Patients take ticagrelor ( In case patient contraindication ASA . Contraindication record accordance local PI CRFs ) Patients sign Data release consent form prior enrollment surveillance Patients hypersensitivity ingredient drug moderate severe hepatic impairment medical history intracranial hemorrhage Patients pathological hemorrhage time administration Patients administrate strong CYP3A4 inhibitor</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Unstable angina</keyword>
</DOC>